Resistance Mechanisms in Melanoma to Immuneoncologic Therapy With Checkpoint Inhibitors

doi 10.20517/cdr.2019.28
Full Text
Abstract

Available in full text

Date
Authors
Publisher

OAE Publishing Inc.

Related search

Rechallenge With Checkpoint Inhibitors in Metastatic Melanoma

JDDG - Journal of the German Society of Dermatology
Dermatology
2020English

Immune Checkpoint Inhibitors Therapy in Older Patients (≥ 70 Years) With Metastatic Melanoma: A Multicentre Study

Postepy Dermatologii I Alergologii
DermatologyAllergyImmunology
2019English

Recurrent Pneumonitis in Patients With Melanoma Treated With Immune Checkpoint Inhibitors

Oncologist
Cancer ResearchMedicineOncology
2019English

Mechanisms and Strategies to Overcome Resistance to Molecularly Targeted Therapy for Melanoma

Cancer
Cancer ResearchOncology
2017English

Immune Checkpoint Inhibitors in Melanoma: Review and Update

Journal of the Portuguese Society of Dermatology and Venereology
2018English

Immune Response in Melanoma: A Basis to Understand the Role of Immunotherapy With Immune Checkpoint Inhibitors

Revista da Sociedade Portuguesa de Dermatologia e Venereologia
2018English

Resistance to Immune Checkpoint Inhibitors. Next Steps and Combinational Approaches

Memo - Magazine of European Medical Oncology
OncologyHematology
2019English

Checkpoint Blockade Therapy Resistance in Hodgkin's Lymphoma

The Lancet
Medicine
2018English

Patterns of Failure After Immunotherapy With Checkpoint Inhibitors Predict Durable Progression-Free Survival After Local Therapy for Metastatic Melanoma

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy